Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04251169
Title Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression (TATEN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group
Indications

Her2-receptor negative breast cancer

Therapies

Paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.